<DOC>
	<DOC>NCT02949908</DOC>
	<brief_summary>This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) subjects on Rebif after discontinuing initial first-line treatment.This study is a regional study with 3 participating countries: Belgium, the Netherlands and Switzerland</brief_summary>
	<brief_title>MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male or female, 18 to 65 years of age (both inclusive), at the time of informed consent Subjects diagnosed with RRMS according to McDonald criteria 2010 Subject have discontinued treatment with dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), glatiramer acetate (Copaxone®), intramuscular IFNβ1a (Avonex®), pegylated interferon (Plegridy®), subcutaneous IFNβ1b (Betaferon®) or fingolimod (Gilenya®) within 6 months prior to Visit 1 Currently treated with Rebif using RebiSmart 2.0, for a maximum of 6 months prior to Visit 1 Subjects have a score on the Expanded Disability Status Scale (EDSS) between 0 to 5.0 inclusive Subjects willing and able to give informed consent. Subjects have known planned surgical procedures at the time of the informed consent that will prevent adherence to treatment with Rebif through RebiSmart 2.0 Subjects diagnosed with primary progressive, secondary progressive, or progressive relapsing MS pregnant or lactating, or planning to become pregnant subjects In the opinion of the Investigator has significant renal or hepatic impairment or other significant disease (e.g., cognitive or visual impairment) that would compromise adherence and completion of the study Reports any reason that he/she cannot complete the 1 year study Subjects have a history of hypersensitivity to natural or recombinant interferon, or any other component of the formulation Subjects who contraindicated for the treatment with subcutaneous IFNβ1a therapy as per summary of product characteristics or currently approved specific country product information Subjects have any other factor that in the opinion of the Investigator would make the subject unsuitable for participation in this study Subjects have significant psychiatric symptoms that, in the opinion of the Investigator, would impact patient ability to comply with treatment recommendations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Rebif</keyword>
	<keyword>Treatment Satisfaction Questionnaire for Medication Version II</keyword>
	<keyword>Multiple Sclerosis International Quality of Life Questionnaire</keyword>
</DOC>